SkinBioTherapeutics (GB:SBTX) has released an update.
SkinBioTherapeutics, a company dedicated to skin health, has announced the conversion of £100,000 in convertible bonds into over 1.1 million ordinary shares, following a notice from Macquarie. These new shares are to be admitted to AIM, raising the company’s total issued shares and voting rights to 203,372,037. This strategic financial move is part of the company’s ongoing efforts to advance its skin healthcare technology and product offerings, including a supplement for psoriasis.
For further insights into GB:SBTX stock, check out TipRanks’ Stock Analysis page.
